ABSTRACT
Introduction
the surgical management of the patient receiving oral antiplatelet drugs is an area of great interest to oral and maxillofacial surgeons. A significant percentage of the population receives antiplatelet therapy for prevention and treatment of thromboembolic diseases such as myocardial infarction, ischaemic stroke, peripheral arterial insufficiency (14, 16) . Although antiplatelet medication include Aspirin ® (ASA), clopidogrel, dipyridamole, non-steroidal antiinflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors, low dose ASA (75-300 mg, daily) is the most common medication, which is used for prophylaxis aganist arterial thrombosis (20, 23) . ASA inhibits irreversibly platelet aggregation within one hour of ingestion and this lasts for the life of platelets (7-10 days). When platelets are inhibited it takes longer time for free blood flow from a cut to stop and for primary haemostasis to occur i.e the bleeding time (Bt) is prolonged (8, 17, 20) .
in the literature, most of the studies have suggested to stop ASA therapy because of the risk of prolonged bleeding after surgery (9, 12, 22) . however, interruption of the drugs may increase the risk of serious thromboembolism, myocardial infarction or cerebrovascular accident (12, 13, 22) . it has been a dilemma of whether antiplatelet therapy should be altered or not before minor oral surgery. Recently several authors suggested that ASA therapy can be maintained and subsequent postextraction haemorrhage are treated by local measures (3, 7, 15) .
Although low dose ASA are used widely in patients with cardiovascular disease, the range is different and depend on the patients' systemic conditions such as gastric intolerance. Most of the authors have reported the effect of lower doses of ASA without interruption of the treatment with ASA. however, there is no study on the effect of different daily doses of ASA after dental extractions without stopping the drug.
Few trials examined the bleeding that was secondary to dental procedures after therapy with daily doses of ASA in the range of 75 mg to 100 mg. however, there was only one study in the literature with ASA doses greater than 100 mg per day (3) . the present study assessed the bleeding risk after dental extractions among patients on different daily doses of ASA in the range of 75mg to 300mg.
Materials and Methods
this study involved ninety-eight extractions in 44 patients who received ASA therapy with different indications, and who were referred to our clinic for dental extractions. All patients were randomly divided into two groups: patients with interrupted ASA therapy 7 days before dental extractions served as a control group; while the study group consisted of patients taking ASA regimen regularly. Decision for interruption of the ASA therapy, were made by the patient's cardiologist. each group was divided into two subgroups according to the used daily dose of ASA (75-150mg and 150-300mg). the exclusion criteria were as follows: oral contraceptives, hormone replacement therapy, other anticoagulation, any other drug such as nSAiDs that could interact with the ASA, patients with a known liver disease, and those taking drugs likely to affect liver function or to produce any effect either directly or indirectly on haemostasis. Procedures were performed with the understanding and written consent of each subject and according to ethical principles, including the World Medical Association Declaration of helsinki.
At the initial consultation a past medical history, clinical and radiological examinations were recorded. Bleeding time was measured with the ivy method in all patients one hour before the extraction procedure. Dental extractions were done under local anaesthesia using Mepivacaine hcl 3% (isocaine, Novocol, NY, USA). Local infiltration and regional blocks were used in the mandible and maxilla as appropriate. the protocol for controlling postoperative bleeding consisted of (a) local pressure by soaked gauze applied for 15 minutes; (b) resorbable gelatin sponge for 15 minutes; (c) sutures for 30 minutes; (d) locally applied tranexamic acid. control of the bleeding was followed up at 15, 30, 60 minutes, 24, 48 hours and 1 week, after the procedure. the paired student's test and Spearman's rank correlation were used in the statistical analyses of the data and comparisons were considered significant at p<0.05.
Results and Discussion
Patient characteristics are shown in Table 1 . the control group consisted of 19 patients (6 female and 13 male) with a mean age of 64.32±10.74 years (range 44 to 86) while 25 patients (15 female and 10 male) with a mean age of 62.84±11.01 years (range 44 to 83) served as a study group. the most commonly used dose of ASA was 75-100 mg in both groups. There were significant differences in the bleeding time between the control and study groups (p<0.01). Significant positive correlation was found between the bleeding time and daily ASA dose (Fig. 1) . in one patient bleeding time was 12.3 min within the normal limits and bleeding was controlled with gauze soaked with resorbable gelatin sponge application for 15 min.
Marketplace-25 (56.8%) was the most common indication for ASA therapy in control and study groups: 14 (31.8%) and 11 (25%) patients, respectively ( Table 2) .
in the control group the most common localization of extractions was in the mandible (30 extractions, 30.6%) whereas in the study group it was observed in the maxilla (31 extractions, 30.6%). Significant correlation between bleeding time and localization of the teeth was not found in both groups. the distributions of the extracted teeth in both groups in terms of bleeding control are shown in Fig. 2a and Fig. 2b . in local haemostatic measurements gauze-soaked (46%) and gauze soaked with resorbable gelatin (44%) were equivalent in study groups. the gauzed-soaked was involved in a higher percentage of cases (87%) in the control group. A statistically significant differences were found in terms of bleeding control between control and study group (p=0.008). Table 4 shows bleeding in patients subdivided by the daily ASA doses. the Bt was prolonged when the dose of ASA increased. the correlation between the dose of ASA and Bt was significant (p=0.001). ASA is still the most common antiplatelet drug used for treatment and prevention of thromboembolic diseases by irreversibly inactivating (for the life of the platelet) the enzyme cyclooxygenase (COX). This enzyme is responsible for the formation of prostaglandins and thromboxane A 2 , which are involved in platelet activation and aggregation mechanisms (2, 3, 7, 11, 15) .
Platelet adhesion, activation, and aggregation are important steps in the formation of a thrombus, thus explaining in a simplified way the antiplatelet effect of ASA (15, 20) . The antiplatelet properties of ASA are effective up to 320 mg daily (19) . Accordingly, ASA is maximally effective as an antiplatelet agent at doses much lower than those required for anti-inflammatory and analgesic functions. Doses of ASA higher than 320 mg daily may be less effective as an antiplatelet because of inhibition of prostacyclin production (2) . evidence based studies have suggested that daily doses of ASA in the range of 75 to100 mg were optimal for the longterm prevention of serious vascular events in high risk patients (2, 19) . however, recent data from randomized clinical trials indicate that the optimal dose of ASA to prevent myocardial infarction and stroke is 160 mg per day (10) .
in the present study, most of the patients used ASA for prophylaxis against cardiovascular disease without a prescription from a physician. the doses of taken daily ASA differed individually from 75 mg to 300 mg and this dose differences did not affect the Bt results.
the oral and maxillofacial surgeon is frequently required to treat patients who are receiving ASA therapy for prophylaxis against myocardial infarction, ischaemic stroke, peripheral arterial insufficiency. Although, low doses of ASA can prevent cardiovascular disease outcomes, also the risk for bleeding after dental extraction may be increased. original recommendations had been made for the discontinuation of ASA use for 7 to 10 days prior to surgical procedures (4, 9, 18, 22, 24) . More recently, it was discussed that ASA can be discontinued for 3 days, which would ensure that a sufficient number of new platelets are released into the circulation. nevertheless, interruption of the ASA therapy may expose these patients at risk of developing thromboembolism, myocardial infarction, or cerebrovascular accident (25) . therefore, there has been some debate as to whether, prior to minor oral surgery, antiplatelet treatment should be altered or not; the risk of serious postoperative haemorrhage has to be balanced against the potential for life-threatening thromboembolism. the literature does not support the routine withdrawal of antiplatelet therapy before dental treatment for patients who are taking such medications (1, 3, 6, 7, 15) . Recently, several authors suggested that levels of antiplatelet drugs are to be maintained and that any subsequent post-extraction haemorrhage is to be treated with local measures (12, 14, 22) . in this study, of the local haemostatic measurements, the gauzed-soaked was involved in a higher percentage of cases (87%) in the control group whereas gauze-soaked (46%) and gauze soaked with resorbable gelatin (44%) were equivalent in the study group and only one patient experienced increased intra-operative bleeding that was adequately controlled with local measures.
literature showed that most of the authorities were in favour of stopping ASA therapy (4, 9, 12, 18, 24) . however, several authors reported that most minor oral surgeries can be carried out safely without stopping long-term low-dose ASA regimen (3, 15) . Ardekian et al. (2000) reported that daily dose of 100 mg of ASA did not significantly increase intra-operative and postoperative bleeding during tooth extractions (3) . Similar results were found in a study of 51 patients on 75-100 mg of
